E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Respiratory Tract Diseases [C08] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.0 |
E.1.2 | Level | PT |
E.1.2 | Classification code | 10003553 |
E.1.2 | Term | Asthma |
E.1.2 | System Organ Class | 10038738 - Respiratory, thoracic and mediastinal disorders |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The primary aim of the study is to evaluate the effect of two formulations of CHF 1535 100/6 µg pMDI on AX (Area under the curve of Reactance) 0-60 minutes post IMP administration in asthmatic patients.
|
|
E.2.2 | Secondary objectives of the trial |
• To evaluate the effect of two formulations of CHF 1535 100/6 µg pMDI on airway hyperresponsiveness (as methacholine PC40 R5) and reactivity (as Response Dose Ratio, RDR) in asthmatic patients. • To evaluate the effect of two formulations of CHF 1535 100/6 µg pMDI on pre- and post-challenge impulse oscillometry and PK profile.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Male or female patients aged 18 years and above. - Patient’s written informed consent obtained prior to any study related procedures. - Patients with established diagnosis of persistent asthma for at least 6 months according to international guidelines. - Patients on 400-2000μg BDP equivalent of Inhaled Corticosteroids (ICS) per day +/- 2nd/3rd line therapy. - Patients with Forced Expiratory Volume in 1 second (FEV1) ≥ 60% predicted at screening. - Patients with methacholine PC40 R5 ≤ 8mg/ml at screening. - Non- or ex-smokers who smoked ≤ 5 Pack-years and quitted smoking > 1 year prior to screening - Female patients must be either of non-childbearing potential or childbearing potential fulfilling one of the following criteria: o with fertile male partners: they and/or their partner must be willing to use a highly effective birth control method from the signature of the informed consent and until the follow-up contact or o with non-fertile male partners (contraception is not required in this case).
|
|
E.4 | Principal exclusion criteria |
- Patients with any other respiratory diseases such as Chronic Obstructive Pulmonary Disease, bronchiectasis or Allergic Bronchopulmonary Aspergillosis, which in the opinion of the investigator are considered to be clinically significant and may have an impact on the study outcomes. - Patients with an asthma exacerbation or respiratory tract infection requiring systemic steroids and/or antibiotics within 1 month of the study commencement or 3 months if hospital admission was required or during the run-in period. - Exercise-induced, seasonal asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine. - Patients with any known systemic clinically significant medical condition, and communicable disease that may endanger the health or safety of the patients. - Female patients who are pregnant or lactating.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Average AX over 60 minutes profile |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
AX post chronic IMP administration (V2 and V4) measured over 60 minutes vs AX baseline before the first IMP administration (V1 and V3)
|
|
E.5.2 | Secondary end point(s) |
• R20, R5-R20, R5, X5 and RF post chronic IMP administration (V2 and V4)over 60 minutes profile • AX, R20, R5-R20, R5, X5 and RF IOS pre-IMP at V2/V4, using IOS baseline parameters at V1/V3 as covariates • Average AX over 60 minutes profile with IOS pre-IMP (collected at V2/V4) instead of IOS baseline (collected at V1/V3) as covariate • PC40 R5 during methacholine challenge at V2/V4 • RDR (Response dose ratio) |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
• R20, R5-R20, R5, Respiratory System Reactance at 5 Hertz (X5) and Resonance Frequency (RF) post chronic IMP administration (V2 and V4) measured over 60 minutes vs R20, R5-R20, R5, X5 and RF baseline before the first IMP administration (V1 and V3) • AX, R20, R5-R20, R5, X5 and RF IOS pre-IMP at V2/V4 versus IOS baseline (pre-IMP) at V1/V3; • at V2/V4 IOS profile post IMP versus IOS pre-IMP; • PC40 R5 and RDR (Response dose ratio) during methacholine challenge at V2/V4
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Yes |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.6.13.1 | Other scope of the trial description |
Compare the commercialized formulation and the alternative formulation |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| Yes |
E.8.4 | The trial involves multiple sites in the Member State concerned | No |
E.8.4.1 | Number of sites anticipated in Member State concerned | 1 |
E.8.5 | The trial involves multiple Member States | No |
E.8.5.1 | Number of sites anticipated in the EEA | 1 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
1-2 weeks after last subject performed visit 4 |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 6 |